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Valeriana officinalis	has	been	extensively	used	as	a	herbal	 remedy	 in	 traditional	medicine.	
However,	there	is	no	clear	evidence	on	the	antinociceptive	effects	of	this	plant.	The	aim	of	
our	study	was	 to	evaluate	 the	effect	of	Valeriana officinalis	hydroalcoholic	extract	on	pain	
modulation	 and	 its	 possible	 mechanism	 in	 mice.	Adult	 male	 Balb/c	 mice	 were	 randomly	
divided	into	nine	experimental	groups.	They	received	i.p.	injections	of	saline,	hydroalcoholic	
root	 extract	 of	 Valeriana officinalis	 (800,	 200,	 or	 50	 mg/kg),	 and	 morphine;	 four	 groups	
received	Valeriana (800	 mg/kg)	 +	 antagonists	 of	 the	 systems	 involved	 in	 antinociception	
effects,	 naloxone,	 ondansetron,	 metoclopramide,	 or	 scopolamine.	 Tail-flick	 and	 writhing	
tests	were	used	for	estimation	of	possible	modulation	of	pain.	The	tail-flick	latencies	in	the	
Valeriana	800	and	200	mg/kg,	but	not	50	mg/kg,	morphine,	and	combined	Valeriana	800	+	 
+	naloxone,	ondansetron,	metoclopramide,	or	scopolamine-treated	groups	were	significantly	
longer	than	that	 in	the	control	group.	However,	 the	tail-flick	latencies	in	the	Valeriana 800	
mg/kg	+	ondansetron-	and	metoclopramide-treated	groups	were	significantly	shorter	than	that	
upon	single	action	of	the	extract	(800	mg/kg).	The	numbers	of	writhings	in	the	extract-treated	
groups	 were	 smaller	 than	 in	 the	 control	 one.	 The	 numbers	 of	 writhings	 in	 the	 Valeriana 
(800	mg/kg)+	ondansetron-	and	metoclopramide-treated	groups	were	significantly	greater	than	
in	the	extract	(800	mg/kg)	group.	It	is	concluded	that	Valeriana officinalis	extract	possesses	a	
clear	analgesic	effect	and	works	through	the	serotonergic	and	dopaminergic	systems.
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INTRODUCTION
In	recent	years,	there	has	been	significant	scientific	progress	
in	 the	 neurobiology	 of	 pain	 control	 and	 introduction	 of	
the	respective	modern	technologies.	Nonetheless,	we	still	
need	new	analgesic	drugs	with	better	efficacy	and	lesser	
side	effects.	There	are	several	approaches	allowing	us	to	
use	metabolites	and	compounds	derived	from	known	and	
novel	plants	to	make	these	drugs	[1].
Valeriana officinalis	 is	 a	well-known	plant	growing	
wild	 in	America	 and	 Eurasia	 [2]	 and	 commonly	 used	
in	traditional	medicine	[3].	According	to	many	studies, 
Valeriana	possesses	sedative,	anxiolytic,	 tranquilizing,	
spasmolytic,	 and	 anticonvulsant	 effects	 [4-8].	 The	
practical	lack	of	side	effects	and	low	price	are	features	
that	make	Valeriana	 so	common	[9].	Valeriana ,	when	
producing	hypolocomotor	 and	axiolytic-like	 effects	 in	
rats,	did	not	alter	oxidative	stress	parameters	in	the	CNS,	
liver,	and	kidneys	[10].
Alkaloids,	lignan,	flavonoids,	GABA,	and	valerenic	acid	
are	active	compounds	found	in	Valeriana officinalis	extracts	
[6,	11,	12].	According	to	a	few	investigations,	flavonoids	
exert	antinociceptic	effects,	and	Valeriana alkaloids	are	also	
members	of	the	analgesic	complement	family	[1,	13,	14].	
As	we	see,	Valeriana 	has	a	number	of	positive	effects	on	
the	nervous	system,	but	there	are	no	direct	studies	related	to	
possible	antinociceptive	effects	of	this	remedy.	The	aim	of	
our	study	was	to	estimate	the	analgesic	activity	of	different	
doses	of	 the	extract	 from	this	plant	and	also	 to	discover	
possible	mechanisms	underlying	its	action.
METHODS
Animals. Adult	male	Balb/c	mice	weighing	25-35	g	were	
obtained	 from	 the	 Iran	 Pasteur	 Institute,	 Tehran.	 They	
were	kept	 at	 a	 constant	 temperature	of	 22	±	2°C	with	 a	
12/12-h	light/dark	cycle	(lights	on	at	7:00	a.m).	Food	and	
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water	were	 available	ad libitum	 in	 the	home	cages.	The	
animals	were	 acclimated	 to	 the	 environment	 for	1	week	
before	 the	 experimental	 procedure.	 All	 procedures	 and	
experiments	were	performed	between	10:00	and	14:00.	
Herbal Material and Extraction. Dried	 roots	 of	
Valeriana officinalis	were	purchased	from	the	Herbal	
Medicine	 Research	 Center	 in	 Hamadan,	 Iran.	 The	
ground	 material	 was	 immersed	 in	 70%	 ethanol	 for	 
72	h	at	room	temperature.	The	extract	was	filtered	and	
then	freezer-dried.
Tail-Flick Test. A	tail-flick	apparatus	for	mice	was	
used	to	produce	radiant	heat	on	the	mouse	tail	(about	3	cm	
from	the	tip).	The	heat	intensity	was	adjusted	such	that	
the	mean	tail-flick	latency	(TFL)	was	about	3	sec,	and	
a	maximum	cut-off	time	of	8	sec	was	set	to	avoid	tissue	
damage.	Mice	were	randomly	divided	into	nine	groups	 
(n	=	8	each).	These	groups	received	saline	(control	group),	
dry	Valeriana extract	(800,	200,	or	50	mg/kg)	dissolved	
in	saline,	morphine	(1	mg/kg;	positive	antinociception	
control	 group),	 and	 co-administrations	 of	 Valeriana 
(800	 mg/kg)	 with	 naloxone	 (a	 blocker	 of	 opioid	
receptors,	 4	 mg/kg),	 ondansetron	 (an	 antagonist	 of	
the	 serotonergic	 system,	 0.5	mg/kg),	metoclopramide	
(an	 antagonist 	 of	 the	 dopaminergic	 system,	 
1	mg/kg),	or	scopolamine	(an	antagonist	of	muscarinic	
cholinoreceptors,	1	mg/kg).	Three	tail-flick	trials	(with	
1-min-long	intertrial	 intervals)	were	performed	before	
and	 after	 drug	 administration.	 The	 TLF	 for	 each	 rat	
was	 calculated	 as	 the	 average	 of	 three	 consecutive	
measurements. 
Acetic Acid Writhing Test. This	 test	 is	 based	 on	
chemical	induction	of	visceral	pain.	Acetic	acid	(0.6%	in	
saline,	0.1	ml/10	g	body	mass)	was	administered	by	i.p	
injections.	Immediately	after	administration,	each	animal	
was	placed	inside	a	transparent	Plexiglas	box.	The	number	
of	abdominal	writhes	accompanied	by	elongation	of	the	
body	 and	 stretching	 of	 the	 hindlimbs	was	 counted	 for	 
30	min.	The	experimental	groups	(n	=	8	each)	were	treated	
similarly	to	what	was	described	for	the	tail-flick	test.
Statistical Analysis. The Student’s	paired	t-test	was	
used	 for	 comparing	 the	 baseline	 and	 post-injection	
TLFs.	 Statistical	 comparisons	 among	 experimental	
groups	 were	 performed	 by	 one-way	 analysis	 of	
variance	 (ANOVA)	 followed	 by	 the	Tukey	 test.	The	
level	 of	P	 <	 0.05	was	 taken	 as	 significant.	Data	 are	
presented	below	as	means	±	s.e.m.
RESULTS
Tail-Flick Test. Statistical	 analysis	 using	 the	 paired	
t-test	 revealed	 that	 i.p.	 injections	 of	 Valeriana 
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F i g. 1.	Changes	 in	 the	 tail-flick	 latency	 (vertical	 scale,	 sec,	before	and	after	treatment)	in	experimental	groups.	The	animals	were	divided	
into	 the	following	groups:	control	(Contr.),	V800	(received	800	mg/kg	of	 the	extract	of	 the	Valeriana officinalis),	V200	(200	mg/kg	Valeriana),	
V50	 (50	mg/kg	Valeriana),	Morph.	 (1.0	mg/kg	morphine),	Nal	 +	V800	 (naloxone	 and	 800	mg/kg	Valeriana),	Ond	 +	V800	 (ondansetron	 and	
800	mg/kg	Valeriana),	Met	 +	V800	 (metoclopramide	 and	 800	mg/kg Valeriana),	 and	 Scop	 +	V800	 (scopolamine	 and	 800	mg/kg	Valeriana).	 
*P <	0.05	and	**P <	0.01,	cases	of	significant	differences	of	post-injection	values	vs.	pre-injection	ones	in	the	same	group.	#P	<	0.05,	##P	<	0.01,	and	
###P	<	0.001,	significantly	different	compared	to	the	control	group.	+P <	0.05,	and	+++P	<	0.001,	significantly	different	compared	to	the	V800	group.	
Each	column	represents	means	±	s.e.m.	
Р и c. 1.	Середні	значення	латентного	періоду	відсмикування	хвоста	(вертикальна	шкала,	с)	в	експериментальних	групах	перед	
уведенням	тестованих	агентів	та	після	цього.	
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extract	 at	 doses	 of	 200	 and	 800	 mg/kg	 (but	 not	 of	
50	 mg/kg),	 morphine,	 and	 Valeriana	 (800	 mg/kg)	 
with	 naloxone,	 ondansetron,	 metoclopramide,	 and	
scopolamine	 significantly	 increased	 the	 TFL,	 as	
compared	with	the	pretreatment	(Fig.	1).	Comparison	
of	 the	 TFL	 using	 one-way	 ANOVA	 indicated	 that	
there	 were	 no	 significant	 differences	 between	 the	
experimental	groups	before	 treatment	 (P	>	0.05),	but	
the	differences	were	highly	significant	after	treatment	 
(P	<	0.0001).	The	Tukey	post-hoc	test	showed	that	the	
TFL	values	showed	no	significant	difference	between	the	
Valeriana (800	mg/kg)	and	morphine	groups,	Valeriana 
(800	mg/kg)	+	naloxone,	and	Valeriana (800	mg/kg)	+	 
+	 scopolamine.	 However,	 the	 TFL	 mean	 value	 in	
the Valeriana	 (800	 mg/kg)	 group	 was	 significantly	
greater	 than	 TFLs	 in	 the	 groups	 that	 received	
200	 and	 50	 mg/kg	 of	 the	 Valeriana	 extract,	 
Valeriana (800	mg/kg)	+	ondansetron,	 and	Valeriana 
(800	mg/kg)+	metoclopramide	(Fig.	1).	
Writhing Test. Statistical	 analysis	 by	 one-
way	 ANOVA	 showed	 that	 there	 were	 significant	
differences	 in	 the	 number	 of	 writhings	 between	
animal	 groups	 (P 	 <	 0.0001).	 The	 Tukey	 post-
hoc	 test	 indicated	 that,	 except	 for	 the	 Valeriana 
(50	 mg/kg)	 group,	 the	 numbers	 of	 writhings	 in	
other	 groups	 were	 significantly	 smaller	 than	
those	 in	 the	 control	 group.	 Also,	 there	 were	 no	
significant	 differences	 in	 the	 number	 of	 writhings	
between	 the	 mouse	 groups	 treated	 with	 Valeriana 
(800	 mg/kg),	 Valeriana (800	 mg/kg)	 +	 naloxone,	
and 	 Valer iana  (800mg/kg) 	 + 	 scopolamine .	
However,	 the	 mean	 numbers	 of	 writhings	 in	 the	
two	 Valeriana-treated	 groups	 (50	 and	 200	 mg/kg),	 
800	mg/kg	Valeriana +	ondansetron,	 and	800	mg/kg 
Valeriana +	 metoclopramide	 were	 significantly	
greater	 than	 those	 in	 mice	 that	 received	 only	 
800	mg/kg	Valeriana (Fig.	2).	
DISCUSSION
Progress	in	developing	analgesic	drugs	has	been	rather	
significant	in	recent	years,	but	the	need	for	drugs	with	
better	effects	remains.	Herbal	medicine	and	the	use	of	
medicinal	plants	is	one	of	the	main	ways	to	meet	this	
need,	and	more	and	more	investigations	are	performed	
in	this	field.
Valeriana ofiicinalis	 in	 Eurasia	 and	 America,	
Valeriana wallichi	in	India,	and	Valeriana angustifolia 
in	 China	 and	 Japan	 are	 species	 of	 Valeriana that 
are	 extensively	 used	 for	 calming,	 sleep	 induction,	
and	 sedative	 effects	 in	 different	 nations.	Valeriana 
decreases	the	general	activity	of	the	CNS	via	inhibiting	
GABA	 breakdown	 in	 particular	 [9,	 12,	 15,	 16].	 
Valeriana 	 is	 also	used	 for	 relieving	anxiety	and	 for	
insomnia	[17-19].
To	 our	 knowledge,	 the	 analgesic	 effects	 of	 this	
plant	 have	 not	 been	 estimated	 directly	 until	 now.	
Results	 of	 our	 study	 show	 that	 the	 hydroalcoholic	
extract 	 of 	 Valeriana off icinalis 	 demonstrates	
s i gn i f i c an t 	 dose -dependen t 	 an t i noc i cep t i ve	
effects.	 The	 highest	 (800	 mg/kg)	 dose	 of	 the	
extract	 successfully	 reduced	 somatic	 pain,	 while	 a	 
50	mg/kg	dose	 did	 not.	Ondansetron,	 a	 serotonergic	
system	antagonist,	and	metoclopramide,	a	dopaminergic	
system	antagonist,	 significantly	decreased	 the	effect	
F i g. 2.	 The	 number	 of	 writhings	 (vertical	
scale)	during	30	min	in	 the	acetic	acid-induced	
writhing	 test.	 Experimental	 animals	 were	
divided	 into	 the	 following	 groups:	 control	
(Contr.),	V800	(received	800	mg/kg Valeriana),	
V200	 (200	 mg/kg Valeriana),	 V50	 (50	 mg/kg	
Valeriana),	Morph.	(1.0	mg/kg	morphine),	Nal	+	
V800	(naloxone	and	800	mg/kg Valeriana),	Ond	
+	V800	(ondansetron	and	800	mg/kg Valeriana),	
Met	 +	 V800	 (metoclopramide	 and	 800	 mg/kg 
Valeriana),	and	Scop	+	V800	(scopolamine	and	
800	 mg/kg Valeriana).	 *P <	 0.05,	 **P <	 0.01	
and	***P <	0.001,	compared	to	the	control	group;	 
#P <	0.05,	##P <	0.01,	and	###P <	0.001,	compared	
to	 the	 V800	 group.	 Each	 column	 represents	
means	±	s.e.m.
Р и с. 2.	 Кількість	 „корчів”	 у	 межах	
30-хвилинного	 періоду	 спостереження	
(вертикальна	 шкала)	 в	 оцтовокислотному	
тесті	(індукція	вісцерального	болю).
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of	 the	 extract,	 showing	 that	Valeriana	 blocked	 pain	
via	 its	 influence	on	 the	 respective	pathways.	We	can	
say	that	ondansetron	exerted	a	more	intense	blocking	
effect	 compared	 to	 that	 of	 metoclopramide.	 We	
found	 no	 significant	 difference	 between	 the	 animal	
groups	treated	with	Valeriana	(800	mg/kg), Valeriana 
(800	mg/kg)	+	naloxone,	and	Valeriana (800	mg/kg)	+ 
+	 scopolamine,	 indicating	 that	 the	 antinociception	
effect	 of	 the	 extract	 is	 preserved,	 and	 that	 the	
opioidergic	 and	 cholinergic	 systems	 are	 probably	
not	 involved	 so	 significantly	 in	 the	 induction	 of	
antinociceptic	effects	of	the	Valeriana extract.
The	 antinociceptive	 activity	 was	 also	 clearly	
expressed	 as	 significant	 reduction	 in	 the	 number	 of	
abdominal	writhings	when	compared	to	that	in	control	
animals.	 In	 this	 test,	we	obtained	 results	comparable	
with	 those	 in	 the	 tail-flick	 test.	 The	 numbers	 if	
withings	were	 reduced	with	 increase	 in	 the	 dose	 of	
the	extract;	thus,	the	dose	dependence	of	the	Valeriana 
hydroalcoholic	extract	was	also	quite	clear.	In	this	test,	
ondansetron	and	metoclopramide	also	antagonized	the	
effects	of	the	extract.
Valeriana	may	affect	 the	CNS	by	 interaction	with	
the	serotonin,	GABA,	melatonin,	or	adenosine	systems	
[20].	Long-term	treatment	with	Valeraiana officinalis 
exerted	no	effect	on	the	reduction	of	dopamine	uptake	
in	 the	 striatum	 of	 Wistar	 rats	 [10].	 Aqueous	 and	
methanolic	extracts	of	Valeriana adscendens	 (one	of	
the Valeriana	 species)	 showed	 affinity	with	 respect	
to	 D
1
	 and	 5-HT
1A	
receptors,	 while	 no	 affinity	 with	
respect	 to	noradrenergic	 receptors	has	been	 reported	
[21].	 6-Methylapigenin	 is	 a	 flavonoid	 detected	 in	
Valeriana officinalis.	 This	 flavone	 is	 a	 ligand	 for	 a	
benzodiazepine	binding	site	 in	GABA
A	
receptors	and	
was	reported	to	cause	anxiolytic	effects	in	mice	[22].	
A	 flavonoid,	 1-hydroxypinoresinol,	 derived	 from	
Valeriana officinalis,	 is	a	 ligand	for	5-HT
1A	
receptors	
[23];	these	receptors	were	found	to	be	involved,	with	
high	efficacy,	in	the	central	analgesia	mechanism	[24,	
25].	Hesperidin,	a	 flavonone	glycoside,	was	found	 to	
be	present	 in	Valeriana [11],	and	it	was	reported	 that	
linarin,	another	flavonone	glycoside,	was	also	found	in	
this	plant	[26].	Clear	sedation	[27]	and	antinociception	
[28]	effects	of	hesperidin	have	been	reported	earlier.
Thus,	 the	 antinociception	 effects	 of	 Valeriana 
officinalis	have	been	assessed	quite	obviously.	These	
effects	 are	 significantly	antagonized	by	ondansetron	
and	 metoclopramide.	 Naloxone	 and	 scopolamine	
exerted	 much	 smaller	 influences	 on	 the	 Valeriana 
hypoalgezic	effects	in	the	tail-flick	and	writhing	tests.	
We	 can	 conclude	 that	 the	 antinociception	 effects	 of	
this	 remedy	 are	 mediated	 by	 the	 serotonergic	 and	
dopaminergic	 systems,	 and	 flavonoids	 affect	 the	
latter.	These	pathways	have	not	been	reported	for	the	
Valeriana officinalis	 effects	 earlier,	 and	 our	 results	
may	 serve	 as	 a	motivation	 for	 further	 investigations	
in	this	field.
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Р	е	з	ю	м	е
Валеріана	 лікувальна	 (Valeriana officinalis)	 широко	
використовується	 як	 рослинний	 лікувальний	 засіб	
у	 традиційній	 медицині. 	 Достовірні	 відомості	 про	
можливу	 антиноцицептивну	 дію	 цієї	 рослини,	 проте,	
були	 відсутні.	 Ціллю	 нашого	 дослідження	 було	 оцінити	
в	 експериментах	 на	 мишах,	 чи	 здатний	 водноспиртовий	
екстракт	 валеріани	 модулювати	 біль,	 а	 також	 з’ясувати	
можливі	 механізми	 таких	 ефектів.	 Дорослі	 самці	 мишей	
лінії	Balb/c	 були	рандомізовано	поділені	 на	 дев’ять	 груп.	
Їм	 внутрішньоочеревинно	 ін’єкували	 фізіологічний	
розчин,	 водноспиртовий	 екстракт	 з	 коренів	 валеріани	
(800,	200	або	50	мг	сухої	речовини	на	1	кг	маси),	морфін,	
а	 в	 чотирьох	 групах	 –	 комбінації	 800	 мг/кг	 екстракту	
валеріани	з	антагоністами	систем,	 залучених	у	реалізацію	
антиноцицептивних	ефектів,	–		налоксоном,	ондасетроном,	
метоклопрамідом	або	скополаміном.	Для	оцінки	можливої	
модуляції	 болю	 використовували	 тест	 відсмикування	
хвоста	та	оцтовокислотний	тест	„корчів”.	Латентні	періоди	
відсмикування	хвоста	в	групах,	що	отримували	800	та	200	
(але	не	50)	мг	екстракту	та	комбіновані	 ін’єкції	800	мг/кг	
валеріани	 із	вказаними	блокаторами,	були	довшими,	ніж	у	
групі	контролю.	В	той	же	час	латентні	періоди	цієї	реакції	в	
групах	800	мг/кг	екстракту	+	ондасетрон	та	метоксипрамід	
були	вірогідно	меншими,	ніж	при	ізольованій	дії	800	мг/кг	 
екстракту.	 Кількість	 „корчів”	 у	 мишей	 у	 межах	 періоду	
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спостереження	у	відповідному	тесті	після	ін’єкції	екстракту	
була	меншою,	ніж	у	контролі.	Число	таких	„корчів”	у	групах	
800	 мг/кг	 екстракту	 в	 комбінаціях	 із	 ондасетроном	 та	
метоклопрамідом	було	вірогідно	більшим	порівняно	з	тим,	
що	спостерігалось	у	разі	дії	лише	екстракту	в	аналогічної	
кількості.	 Зроблено	 висновок,	 що	 екстракт	 валеріани	
здійснює	очевидний	аналгетичний	вплив,	опосередкований	
серотонін-	та	дофамінергічною	системами.
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